Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | INKT | Common Stock | Purchase | $139K | +129K | +0.6% | $1.08 | 21.5M | May 3, 2023 | Direct | F1, F2 |
transaction | INKT | Common Stock | Purchase | $26.2K | +21.5K | +0.1% | $1.22 | 21.5M | May 4, 2023 | Direct | F2, F3 |
transaction | INKT | Common Stock | Purchase | $94.9K | +100K | +0.47% | $0.95 | 21.6M | May 5, 2023 | Direct | F4 |
transaction | INKT | Common Stock | Purchase | $250 | +200 | +0% | $1.25 | 21.6M | May 5, 2023 | Direct |
Id | Content |
---|---|
F1 | Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20). |
F2 | Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. |
F3 | Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25). |
F4 | On May 5, 2023, Agenus purchased 100,000 shares of MiNk Therapeutics, Inc. common stock from Garo Armen, Agenus's Chairman and CEO, at the same price he paid to acquire the shares on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close. |